Vericel Corporation to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025
Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL)
CCORF Maintains Vericel(VCEL.US) With Buy Rating, Raises Target Price to $67
Vericel Is Maintained at Buy by Canaccord Genuity
Optimistic Long-Term Growth Outlook for Vericel Despite Recent Setbacks
H.C. Wainwright Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $60
CCORF Maintains Vericel(VCEL.US) With Buy Rating, Raises Target Price to $64
JPMorgan, Goldman, Citigroup, BlackRock, D-Wave Quantum: Biggest Movers
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
TD Cowen Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $72
Beyond The Numbers: 5 Analysts Discuss Vericel Stock
TD Cowen Remains a Buy on Vericel (VCEL)
Express News | Market-Moving News for January 15th
Vericel Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Citi Initiates Vericel(VCEL.US) With Buy Rating, Announces Target Price $60
Vericel's Strong Growth Prospects and MACI Product Drive Buy Rating Amid Positive Revenue Trajectory and Future Expansion Plans
JPMorgan, Wells Fargo, Eli Lilly, D-Wave Quantum, and More Stock Market Movers
Closing Bell Movers: Vericel Down 11% After Q4 Pre-announcement
Vericel Shares Fall 10% After 4Q Forecast Misses Estimates
Vericel Sees FY25 Revenue up 20%-23%